Corbus Pharmaceuticals announces abstract accepted for presentation

Corbus Pharmaceuticals Holdings announced that the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 has been accepted for presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium, to be held January 25-27, 2024 in San Francisco, CA and online. CRB-701 is a next-generation antibody-drug-conjugate targeting nectin-4, that contains a third generation, site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Pre-clinical data demonstrating differentiation from enfortumab vedotin was recently presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The abstract is titled: Phase 1 Dose-Escalation of SYS6002, a next-generation Nectin-4 Targeting Antibody Drug Conjugate. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer. The Nectin-4 ADC PADCEV is approved for use in late metastatic urothelial cancer and recently received an expanded label under an accelerated approval from the Food and Drug Administration for use in combination with KEYTRUDA for patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.